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Abstract There has been growing recognition of a changing
clinical presentation of celiac disease (CD), with the
manifestation of milder symptoms. Serologic testing is
widely used to screen patients with suspected CD and
populations at risk. The aim of this retrospective analysis
was to evaluate the clinical presentation of CD in childhood,
assess the diagnostic value of serologic tests, and investigate
the impact of IgA deficiency on diagnostic accuracy. We
evaluated 206 consecutive children with suspected CD on
the basis of clinical symptoms and positive serology results.
Ninety-four (46%) had biopsy-proven CD. The median age
at diagnosis of CD was 6.8 years; 15% of the children were
<2 years of age. There was a higher incidence of CD in girls
(p=0.003). Iron deficiency and intestinal complaints were
more frequent in children with CD than those without CD
(61% vs. 33%, p=0.0001 and 71% vs. 55%, p=0.02,
respectively), while failure to thrive was less common
(35% vs. 53%, p=0.02). The sensitivity of IgA tissue
transglutaminase (IgA-tTG) was 0.98 when including all
children and 1.00 after excluding children with selective IgA
deficiency. The specificity of IgA-tTG was 0.73 using the
recommended cut-off value of 20 IU, and this improved to
0.94 when using a higher cut-off value of 100 IU. All
children with CD and relative IgA deficiency (IgA levels
that are measurable but below the age reference [n=8]) had
elevated IgA-tTG. In conclusion, CD is frequently diagnosed
in school-age children with relatively mild symptoms. The
absence of intestinal symptoms does not preclude the
diagnosis of CD; many children with CD do not report
intestinal symptoms. While the sensitivity of IgA-tTG is
excellent, its specificity is insufficient for the diagnostic
confirmation of a disease requiring life-long dietary restric-
tions. Children with negative IgA-tTG and decreased but
measurable IgA values are unlikely to have CD.
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CD Celiac disease
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Introduction
Celiac disease (CD) is an immune-mediated enteropathy
triggered by the ingestion of gluten, which affects geneti-
cally predisposed individuals [6, 14]. It is one of the most
common life-long disorders, with an estimated prevalence
ranging from 3 to 13 per 1,000 children in the general
population in Europe and North America [14, 15, 19, 28]. A
recent study in asymptomatic adolescents in eastern Switzer-
land revealed a prevalence rate of 1 in 230 adolescents [25].
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There is strong evidence for a higher occurrence of CD in
children with type 1 diabetes mellitus (T1DM), autoimmune
thyroid disease, selective IgA deficiency, Down’ syndrome,
Turner syndrome, and first-degree relatives of patients with
CD [1, 14, 21]. The clinical presentation of CD is very
variable, ranging from the typical syndrome of intestinal
malabsorption starting between the age of 6 and 24 months
to atypical symptoms of other organ systems [10, 14].
Classic symptoms include impaired growth, chronic diar-
rhea, abdominal distention, muscle wasting, hypotonia, poor
appetite, and unhappy behavior.
More recently, a trend towards less symptomatic mani-
festations of CD has been observed. Atypical symptoms
include unusual intestinal complaints, such as recurrent
abdominal pain, vomiting, bloating, and constipation, as
well as extraintestinal manifestations, such as short stature,
pubertal delay, iron deficiency, and abnormal liver function
tests [12–14, 23, 26]. Thus, serologic screening is essential
in the diagnostic approach of this variable disease. IgA
endomysium antibodies (IgA-EMA) and, more recently, IgA
antibodies against tissue transglutaminase (IgA-tTG) offer
better sensitivity and specificity than IgA and IgG antigliadin
(AGA) antibodies [24]. IgA-tTG is recommended for initial
testing for CD by the North American Society for Pediatric
Gastroenterology, Hepatology and Nutrition (NASPGHAN)
[14], because the tTG enzyme-linked immunosorbent assay
(ELISA) test is less interobserver-dependent and less
laborious than the EMA immunofluorescence test. It is
generally accepted that a small-bowel biopsy is required for
diagnostic confirmation [14, 30]. However, due to the
invasiveness of the endoscopic procedure, there is growing
interest in developing diagnostic rules which are sufficiently
reliable to diagnose CD without the need for biopsies, at
least in subsets of patients. In this regard, Barker et al. [3]
and Diamanti et al. [11] have suggested that markedly
elevated IgA-tTG are highly specific and, therefore, small-
bowel biopsies may not be necessary in patients with
markedly elevated IgA-tTG values.
We conducted a retrospective analysis of all children
undergoing an upper endoscopy for suspected CD at the
Children’s Hospitals in Berne and Lucerne to examine the
clinical presentation of CD in central Switzerland. We also
evaluated the diagnostic value of serologic markers consid-
ering different cut-off values and assessed the impact of
selective IgA deficiency on the diagnostic accuracy.
Methods
Study design
We performed a retrospective analysis of all children
(<16 years of age) who underwent upper endoscopy and
small-bowel biopsies for suspected CD between January
2001 and August 2006 at the Children’s Hospitals of Berne
and Lucerne (serving approximately 1.5 million inhab-
itants). For patient identification, endoscopy reports were
retrieved from a computerized database, which prospec-
tively recorded all children undergoing an upper endoscopy.
Database records were checked against filed paper records
of endoscopy reports for completeness. Chart reviews were
performed when there was any note of suspected CD in the
endoscopy reports. Patients were included when serologic
testing was performed because of the presence of sugges-
tive symptoms or to screen patients with conditions
associated with an increased risk for CD or first-degree
relatives. Patients were excluded from the study when
gluten had not been introduced for at least one month prior
to serologic testing. The study was approved by the
Institutional Human Ethics Review Boards.
Using a standardized form, charts were reviewed for
signs and symptoms of CD, first-degree relatives with CD,
conditions associated with CD, as well as the results of
serologic markers and histology reports. All patients were
assessed for intestinal manifestations, including abdominal
pain, diarrhea, constipation, flatulence, weight loss, and
failure to thrive (FTT), and the extraintestinal symptoms,
short stature, anemia and microcytosis, or hypochromasia
as surrogates for latent iron deficiency. Extraintestinal
manifestations without strong evidence for an association
with CD (e.g., epilepsy with occipital calcifications) [14] or
rare occurrence in childhood (e.g., dermatitis herpetiformis)
were not included in our assessment. T1DM, thyroid
disease, Addison disease, Turner syndrome, Down syn-
drome, and juvenile arthritis were considered as conditions
with an increased risk for CD.
Serologic tests and total IgA
Serologic testing (IgA-tTG, IgA-EMA, IgA-AGA, and IgG-
AGA) and total IgA levels were performed in different
laboratories using various assays during the study period.
IgA-tTG was measured by human recombinant or purified
erythrocytes assays, manufactured by INOVA Diagnostics
Inc. (San Diego, USA), Pharmacia Diagnostics GmbH
(Freiburg, Germany), Phadia Diagnostics GmbH (Freiburg,
Germany), and Vita-Diagnostika GmbH (Merzhausen,
Germany). The results from each serologic marker were
classified as either normal or elevated using the respective
cut-off level for each test and assay. As suggested by
Barker et al. [3], we considered IgA-tTG values >100 IU as
markedly elevated for human recombinant or purified
erythrocyte IgA-tTG tests. IgA levels within or above the
normal range for age were classified as normal, IgA levels
<0.05 g/L as absolute IgA deficiency, and IgA levels below
the normal range for age as relative IgA deficiency [18].
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IgA-tTG was only sporadically performed before 2002,
therefore, only patients investigated in 2002 and onwards
were included in the analysis of the serologic tests.
Biopsy
All biopsies were reviewed by experienced pathologists
using Marsh criteria modified by Oberhuber et al. [20, 22].
According to NASPGHAN guidelines [14], children with
Marsh Grade II and III were diagnosed with CD. Children
with normal biopsies were considered as disease controls
(non-CD children); they did not have CD on the basis of the
NASPGHAN criteria [14]. Children with non-specific
changes on biopsy, such as raised intraepithelial lympho-
cytosis (Marsh Grade I), were excluded from the analysis.
Statistical analysis
GraphPad Prism 4 (GraphPad Software Inc., San Diego,
USA) and SigmaPlot Version 11 (Systat Software Inc., San
Jose, USA) were used for the statistical analysis. The
results of descriptive statistics are presented as median,
minimum, and maximum value for data with a skewed
distribution. For the comparison of study groups, the Mann-
Whitney U-test was used for ordinal data and Fischer’s
exact test for categorical data. Significance was established
at p-values<0.05.
Results
In total, 206 children (104 girls) underwent small-bowel
biopsies for suspected CD on the basis of suggestive
clinical symptoms and/or elevated serologic markers in
Berne and Lucerne between January 2001 and August
2006. Normal biopsies were seen in 112 children (54%).
Ninety-four children (46%) met the diagnostic criteria for
CD, of whom 91% had changes consistent with Marsh
Grade III and 9% with Grade II. Four children showed
equivocal results with unspecific changes consistent with
Marsh Grade I and were excluded from the analyses
(Fig. 1).
The number of newly diagnosed children varied between
11 and 22 per year, with fewer cases in 2001 and 2006
(Fig. 2). The median age at diagnosis and the number of
young children (<2 years of age) were similar in each year.
Compared to children in whom CD was excluded (non-CD
group), celiac patients were, on average, older at diagnosis
(6.8 years and 4.9 years, respectively, p=0.03) (Table 1).
There was a smaller percentage of young children (<2 years
of age) in the celiac group (15% compared to 25% without
CD). Significantly more girls were diagnosed with CD
(62% compared to 40%, p=0.003). Patients with CD had a
higher weight than those without CD (weight z-scores =
–1.0 and –1.6, respectively), while their height was similar
(height z-scores = –1.2 and –1.4, respectively). Predispos-
ing factors such as a positive family history or T1DM were
seen in similar proportions in both groups.
Clinical presentation
There was a broad spectrum of clinical symptoms in children
with CD (Table 2). Gastrointestinal symptoms occurred more
often among celiac patients compared to patients without CD
(71% versus 55%; p=0.02). In celiac patients, abdominal
pain and diarrhea were frequent complaints (37% and 39%,
respectively), while abdominal distension, flatulence, and
constipation were less common (20%, 3%, and 7%,
respectively). FTT was less common in celiac patients
(35% versus 53%; p=0.0157). Anemia or microcytosis and
hypochromasia as surrogates for iron deficiency occurred
significantly more often in celiac patients (61% and 33%; p=
0.0001). Overall, the specificity of a single clinical symptom
Fig. 1 Histology results according to Marsh criteria and final
diagnosis for all children (n=206). *Unspecific changes (Marsh Grade
I) were seen in four children; one girl with Addison disease, one girl
with the subsequent diagnosis of a Helicobacter pylori-associated
gastritis, one girl with cystic fibrosis, and one boy with total IgA
deficiency and constipation
Fig. 2 Annual number of newly diagnosed celiac patients and median
age at diagnosis between 2001 and 2006. The boxes represent the
number of newly diagnosed celiac patients per year; the lower dark
part displays the number of new cases under the age of 2 years per
year. The dots represent the median age at diagnosis for each year
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was poor. However, the specificity improved when various
combinations of clinical symptoms were examined. For
example, children presenting with abdominal symptoms and
anemia were more likely to have CD (39% with CD and
17% without CD, p=0.0001).
Serologic tests
IgA-tTG was measured in 167 children, of whom 80 were
diagnosed with CD. IgA-tTG was elevated in all celiac
patients, with the exception of a 4-year-old boy with typical
symptoms, absolute IgA deficiency, and elevated IgG-
AGA. On the other hand, 22 children with normal biopsies
had elevated IgA-tTG using the recommended cut-off
values for the respective assays. In order to assess the
impact of markedly elevated test results, we restricted the
analysis to 132 children (63 with CD and 69 without CD),
in whom IgA-tTG was measured by human recombinant or
purified erythrocyte assays using a cut-off value of 20 IU.
The majority of children with CD (n=48, 76%) had
markedly elevated IgA-tTG values (>100 IU). However,
there were four patients without CD who also had markedly
elevated IgA-tTG values. Among these patients, there was a
14-year-old boy with T1DM who had repeatedly elevated
IgA-tTG and IgA-EMA without clinical symptoms sugges-
tive of CD, and three girls with anemia due to iron
deficiency and no other clinical symptoms of CD.
Overall, the sensitivity and specificity for IgA-tTG was
0.99 and 0.75, respectively (Table 3). When the diagnostic
value of IgA-tTG was examined in groups of patients with
defined clinical presentations, the specificity of IgA-tTG
improved in children who reported symptoms involving
more than one organ system (Table 2). For example, the
specificity of IgA-tTG was 0.93 in children with anemia,
0.98 in children with anemia and gastrointestinal symp-
toms, and 1.00 when anemia, gastrointestinal symptoms,
and FTT or short stature were reported.
IgA-EMA was measured in a smaller number of patients
(n=89), revealing a sensitivity of 0.98 and sa pecificity of
0.86 (Table 3). There was one child with CD who had
elevated IgA-tTG, but normal IgA-EMA. In the majority of
Table 2 Clinical symptoms of children with CD and controls (no CD) and the specificity of clinical symptoms alone or in combination with
elevated IgA-tTG
CD (n=94) No CD (n=108) p-value Specificity
of symptoms
Specificity of symptoms
plus elevated IgA-tTG
I Gastrointestinal symptoms (%) 67 (71) 59 (55) 0.02* 0.45 0.86
Abdominal pain 35 (37) 32 (30)
Diarrhea 37 (39) 30 (28)
II Anemia and/or microcytosis or hypochromasia(%) 57 (61) 36 (33) 0.0001* 0.66 0.93
Anemia 52 (55) 24 (22)
Microcytosis or hypochromasia 16 (17) 18 (17)
III FTT and/or short stature (%) 49 (52) 67 (62) 0.2 0.38 0.91
Failure to thrive 33 (35) 57 (53)
Short stature 16 (15) 10 (9)
I + II (%) 37 (39) 16 (17) 0.0001* 0.85 0.98
II + III (%) 32 (34) 21 (19) 0.025 0.81 0.98
I + II + III (%) 20 (21) 8 (7) 0.0001* 0.93 1
Clinical symptoms are summarized for patients with CD (CD) and controls (no CD). Percentages are given in parentheses (%). Gastrointestinal
symptoms are grouped as I, anemia/iron deficiency as II, and FTT/short stature as III
The specificity is displayed for single clinical symptoms and combinations of various symptoms, as well as for the combination of symptoms plus
elevated IgA-tTG
*p<0.05
Table 1 Characteristics of the study groups
CD
(n=94)
No CD
(n=108)
p-value
Gender, female (%) 58 (62) 43 (40) 0.003*
Age in years,
median (range)
6.8
(0.8–15.1)
4.9
(0.4–15.9)
0.030*
Height z-score,
median (range)
−1.2
(-3.9–3.6)
−1.4
(-4.0–4.3)
0.483
Weight z-score,
median (range)
−1.0
(-4.1–2.7)
−1.6
(-3.7–3.8)
0.021*
Family history
(first-degree relatives)
16 12
Associated conditions
T1DM 6 3
Juvenile rheumatoid arthritis 1 1
Down syndrome 1 1
Addison disease 1 0
*p<0.05
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patients, IgG-AGA and IgA-AGA were measured. While
IgG-AGA showed a relatively good sensitivity of 0.82 and
a poor specificity of 0.37, the sensitivity of IgA-AGA was
only 0.65 and the specificity was 0.79.
Selective IgA deficiency
Total serum IgA was measured in all children. In seven
patients, absolute IgA deficiency was found, of whom two
were diagnosed with CD. Interestingly, one of these two
children had slightly elevated IgA-tTG (26 IU) using the
human recombinant tTG assay. In addition, there were eight
celiac patients with relative IgA deficiency (low values for
age), all having elevated IgA-tTG and IgA-EMA, while
IgA-AGA was elevated in only one child. In total, 26
children with low IgA for age and normal IgA-tTG or IgA-
EMA underwent a small-bowel biopsy, with normal biopsy
results in all children. Excluding patients with absolute IgA
deficiency, the overall sensitivity of IgA-tTG was 1.00 and
the specificity was 0.73.
Discussion
Our retrospective analysis shows that the classic presenta-
tion of CD [10, 14] is not a very common feature of the
disease; a rather small number of children (15%) was
diagnosed under the age of 2 years with the classic triad of
symptoms. A larger number of children presented at an
older age with milder symptoms. During the observation
period of our study, the number of new cases per year and
the median age at diagnosis remained unchanged. As
described in previous reports from several populations, we
found an increased risk for CD in girls compared to boys
[8, 15, 16]. This gender difference may be explained by
genetic factors and, possibly, environmental exposures. It
has been postulated that genetic factors influence immune
responses and, thereby, make girls more susceptible to
environmental exposures that have been associated with an
increased risk for CD, such as the early introduction of
gluten [2, 8, 17].
We revealed that symptoms of intestinal malabsorption
and abdominal pain were frequent complaints. However,
almost one third of celiac patients did not report any
intestinal symptoms. This underlines the importance of a
high suspicion for CD in children presenting with extra-
intestinal symptoms, such as iron deficiency or short stature
[9]. In our cohort, the likelihood of disease increased with
the presence of anemia or microcytosis and hypochromasia
as surrogates for iron deficiency in conjunction with
abdominal symptoms or short stature, or both. Not
surprisingly, the more symptoms the children had, the more
likely they were to have the disease. When children with
CD were compared to our disease control group with
normal intestinal biopsies, the children without CD were,
on average, younger and had more pronounced FTT. In our
view, this rather surprising difference may be explained by
the fact that serologic testing is generally thought to be less
reliable in young toddlers than in older children. Therefore,
young children with normal or mildly elevated serologic
markers (especially IgG-AGA) and/or decreased levels of
total IgA are more likely to undergo intestinal biopsies to
rule out CD. Also, children with more pronounced FTT are
often more aggressively investigated than those with milder
symptoms.
Regarding the diagnostic accuracy of serologic markers,
our analysis confirms excellent sensitivity for both IgA-tTG
and IgA-EMA antibodies (1.00 and 0.98, respectively, in
children without absolute IgA deficiency). In the literature,
sensitivity rates vary between 0.85–0.98, depending of the
prevalence of CD in the respective cohorts and the study
design [12, 27, 29, 31]. In a recent systematic review,
Rostom et al. [24] calculated pooled sensitivity rates for
IgA-tTG and IgA-EMA of 0.90. Although it has been
suggested in previous studies that normal IgA-tTG and
IgA-EMA may occur more often in celiac patients under
the age of 2 years [4, 5], we could not detect any
differences between age groups. The specificity for IgA-
tTG and IgA-EMA, on the other hand, was limited in our
cohort compared to the results from other studies. Rostom
et al. [24] described a pooled specificity of 0.96–0.99 for
IgA-tTG and 0.95–0.97 for IgA-EMA, while in our study,
the specificity was only 0.75 for IgA-tTG and 0.86 for IgA-
EMA, resulting in a considerable number of children with
elevated IgA-tTG and IgA-EMA and normal biopsies. In
order to define subgroups of patients in whom serologic
testing is highly reliable, Barker et al. [3] and Diamanti et
al. [11] suggested distinguishing patients with markedly
elevated IgA-tTG (>100 IU, using human recombinant or
purified erythrocyte assays). However, in our group, we
Table 3 Sensitivity and specificity of celiac antibodies
CD (%) No CD (%) Sensitivity Specificity
IgA-tTG
(n=167)
79 (99) 22 (25) 0.99 0.75
IgA-EMA
(n=89)
45 (98) 6 (14) 0.98 0.86
IgA-AGA
(n=166)
51 (65) 18 (21) 0.65 0.79
IgG-AGA
(n=164)
63 (82) 55 (63) 0.82 0.37
The number of patients with positive results for IgA-tTG, IgA-EMA,
IgA-AGA, and IgG-AGA are displayed for patients with celiac disease
(CD) and controls (no CD). Percentages are given in parentheses. The
sensitivity and specificity were calculated for each test.
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observed four oligosymptomatic children with markedly
elevated IgA-tTG and normal biopsies. Although some of
these patients may develop histological changes over time,
they do not have CD based on the current diagnostic criteria
and, thus, a gluten-free diet is not recommended. When the
diagnostic accuracy of IgA-tTG was evaluated in subgroups
of children with defined clinical symptoms, the specificity
of IgA-tTG was 1.00 in children presenting with the classic
triad of symptoms of intestinal malabsorption, growth
retardation, and iron deficiency. This observation raises the
question as to whether small-bowel biopsies for diagnostic
confirmation are required for all children with the classic
triad of symptoms and highly elevated IgA-tTG or IgA-
EMA. In our view, this diagnostic approach should be tested
in larger cohorts. In patients with borderline elevations of
IgA-tTG, the measurement of IgA-EMA may be useful, as
suggested by Hill et al. [14]. In our cohort, 13 of 22 children
with falsely elevated IgA-tTG had negative IgA-EMA.
IgA-AGA and IgG-AGA did not add diagnostic value to
the screening process in patients without IgA deficiency.
Contrarily, elevated IgA-AGA or IgG-AGA may raise the
suspicion of CD in cases with normal IgA-tTG or IgA-
EMA and, thus, prompt further unnecessary testing.
Absolute IgA deficiency, defined as IgA < 0.05 g/L [18],
and relative IgA deficiency, defined as low for age values,
were relatively common in our cohort. Interestingly, all
children with CD and low IgA for age had elevated IgA-
tTG or IgA-EMA. This observation suggests that children
with decreased, but measurable total IgA levels, are
producing sufficient amounts of IgA antibodies to reliably
rule out CD on the basis of normal IgA-tTG or IgA-EMA
values. In children with absolute IgA deficiency and normal
IgA-tTG or IgA-EMA, the measurement of IgG antibodies
is recommended to improve the sensitivity of the screening
strategy [7]. Due to the lack of measurements of IgG-tTG in
our study, we could not compare the diagnostic accuracy of
different IgG antibodies. According to Rostom et al. [24],
the sensitivity of IgG-AGA was better than IgG-tTG (0.80
compared to 0.40), while the specificity was weaker for
IgG-AGA (0.80–0.90 and 0.98, respectively).
Based on our study results and a review of the literature,
we recommend the routine measurement of either IgA-tTG
or IgA-EMA and total IgA levels as the primary screening
strategy. In patients with absolute IgA deficiency, the
additional measurement of IgG-AGA or IgG-tTG is
recommended.
The validity of our study may be somewhat limited by
biases in the measurement of serologic markers and patient
selection. During the study period from 2001 to 2006,
different assays for IgA-tTG were used by various laborato-
ries. Due to the retrospective study design, we were not able
to determine in all cases which IgA-tTG assay was used. In a
limited analysis comparing IgA-tTG assays using purified
erythrocyte tTG and human recombinant tTG, we could not
detect any difference (data not shown). However, due to the
limited availability and also the reliability of data, the groups
were too small to draw conclusions. In terms of patient
selection, we included all patients who underwent intestinal
biopsies for suspected CD, in whom serologic testing was
done prior to endoscopy, regardless of which serologic tests
had been performed. The vast majority of patients were
investigated because of clinical symptoms of CD. Only a
small subset of patients was screened for CD because of
associated diseases, such as T1DM or a positive family
history. Since many of these patients also reported clinical
symptoms, they were all included in our study.
In summary, CD is frequently diagnosed in school age
children with mild clinical manifestations. Signs and
symptoms suggestive of CD, such as anemia, short stature,
or persistent abdominal complaints, should raise suspicion
and prompt screening, consisting of IgA-tTG or IgA-EMA
and total IgA. In our view, the specificity of IgA-tTG is
insufficient to confidently diagnose a condition requiring a
life-long gluten-free diet. Therefore, a small-bowel biopsy
is generally required for diagnostic confirmation. Further
studies in larger cohorts are needed in order to evaluate
whether histological confirmation is needed in all children,
including those with typical symptoms involving more than
one organ system and markedly elevated IgA-tTG.
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